These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 18833102)

  • 41. Antispasticity medications.
    Nance PW; Young RR
    Phys Med Rehabil Clin N Am; 1999 May; 10(2):337-55, viii. PubMed ID: 10370935
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients.
    Elovic EP; Brashear A; Kaelin D; Liu J; Millis SR; Barron R; Turkel C
    Arch Phys Med Rehabil; 2008 May; 89(5):799-806. PubMed ID: 18452724
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An approach to switching patients from baclofen to tizanidine.
    Brenner R; Hyman N; Knobler R; O'Brien M; Stephan T
    Hosp Med; 1998 Oct; 59(10):778-82. PubMed ID: 9850294
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Occurrence of adverse events in long-term intrathecal baclofen infusion: a 1-year follow-up study of 158 adults.
    Borrini L; Bensmail D; Thiebaut JB; Hugeron C; Rech C; Jourdan C
    Arch Phys Med Rehabil; 2014 Jun; 95(6):1032-8. PubMed ID: 24407102
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after stroke.
    Jahangir AW; Tan HJ; Norlinah MI; Nafisah WY; Ramesh S; Hamidon BB; Raymond AA
    Med J Malaysia; 2007 Oct; 62(4):319-22. PubMed ID: 18551937
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacologic management of spasticity following stroke.
    Gallichio JE
    Phys Ther; 2004 Oct; 84(10):973-81. PubMed ID: 15449979
    [No Abstract]   [Full Text] [Related]  

  • 47. [Effect of Dantrium on spasticity in paraplegic and tetraplegic patients (author's transl)].
    van Laere M; Leus P; Mastelinck C
    J Belge Med Phys Rehabil; 1978; 1(2):189-99. PubMed ID: 757420
    [No Abstract]   [Full Text] [Related]  

  • 48. A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot.
    Mancini F; Sandrini G; Moglia A; Nappi G; Pacchetti C
    Neurol Sci; 2005 Apr; 26(1):26-31. PubMed ID: 15877184
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The underutilization of intrathecal baclofen in poststroke spasticity.
    Dvorak EM; Ketchum NC; McGuire JR
    Top Stroke Rehabil; 2011; 18(3):195-202. PubMed ID: 21642057
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of NABOTA in post-stroke upper limb spasticity: a phase 3 multicenter, double-blinded, randomized controlled trial.
    Nam HS; Park YG; Paik NJ; Oh BM; Chun MH; Yang HE; Kim DH; Yi Y; Seo HG; Kim KD; Chang MC; Ryu JH; Lee SU
    J Neurol Sci; 2015 Oct; 357(1-2):192-7. PubMed ID: 26233808
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Medical treatment of spasticity].
    Rode G; Maupas E; Luaute J; Courtois-Jacquin S; Boisson D
    Neurochirurgie; 2003 May; 49(2-3 Pt 2):247-55. PubMed ID: 12746699
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Summary of combined clinical analysis of controlled clinical trials with tizanidine.
    Wallace JD
    Neurology; 1994 Nov; 44(11 Suppl 9):S60-8; discussion S68-9. PubMed ID: 7970013
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The administration of midocalm in the treatment of vertebrogenic algesic syndromes].
    Avakian GN; Chukanova EI; Nikonov AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2000; 100(5):26-31. PubMed ID: 10849963
    [No Abstract]   [Full Text] [Related]  

  • 54. Pharmacological risks following stroke.
    Smith J
    Phys Ther; 2005 Jan; 85(1):81-2. PubMed ID: 15623365
    [No Abstract]   [Full Text] [Related]  

  • 55. Efficacy and safety study of arbaclofen placarbil in patients with spasticity due to spinal cord injury.
    Nance PW; Huff FJ; Martinez-Arizala A; Ayyoub Z; Chen D; Bian A; Stamler D
    Spinal Cord; 2011 Sep; 49(9):974-80. PubMed ID: 21577221
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term intrathecal baclofen: outcomes after more than 10 years of treatment.
    Mathur SN; Chu SK; McCormick Z; Chang Chien GC; Marciniak CM
    PM R; 2014 Jun; 6(6):506-513.e1. PubMed ID: 24355547
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intrathecal baclofen for muscle spasticity and pain--two case reports.
    Al Khudhairi D; Rababa A; Saddiqui MN
    Middle East J Anaesthesiol; 2006 Jun; 18(5):971-6. PubMed ID: 17094537
    [No Abstract]   [Full Text] [Related]  

  • 58. The pharmacotherapy of spinal spasticity: a decade of progress. II. Therapeutics.
    Segatore M; Miller M
    SCI Nurs; 1995 Mar; 12(1):2-7. PubMed ID: 7792578
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Functional outcome of intrathecal baclofen administration for severe spasticity.
    Boviatsis EJ; Kouyialis AT; Korfias S; Sakas DE
    Clin Neurol Neurosurg; 2005 Jun; 107(4):289-95. PubMed ID: 15885386
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Spasticity and its association with functioning and health-related quality of life 18 months after stroke.
    Welmer AK; von Arbin M; Widén Holmqvist L; Sommerfeld DK
    Cerebrovasc Dis; 2006; 21(4):247-53. PubMed ID: 16446538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.